P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2019
P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2019
SUMMARY
According to the recently published report 'P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2019'; P2X Purinoceptor 3 (P2RX3) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.
P2X Purinoceptor 3 (P2RX3) - P2X purinoceptor 3 is a protein encoded by the P2RX3 gene. It belongs to the family of purinoceptors. This receptor functions as a ligand-gated ion channel and transduce ATP-evoked nociceptor activation. This receptor is important for peripheral pain responses, and also participates in pathways controlling urinary bladder volume reflexes.
The report 'P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2019' outlays comprehensive information on the P2X Purinoceptor 3 (P2RX3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 4 and 3 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.
Report covers products from therapy areas Central Nervous System, Respiratory, Women's Health, Dermatology and Ophthalmology which include indications Chronic Cough, Pain, Neuropathic Pain (Neuralgia), Visceral Pain, Endometriosis, Inflammatory Pain, Alzheimer's Disease, Cough, Insomnia, Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), Obstructive Sleep Apnea, Ocular Hypertension, Open-Angle Glaucoma, Osteoarthritis Pain and Pruritus.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2019'; P2X Purinoceptor 3 (P2RX3) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.
P2X Purinoceptor 3 (P2RX3) - P2X purinoceptor 3 is a protein encoded by the P2RX3 gene. It belongs to the family of purinoceptors. This receptor functions as a ligand-gated ion channel and transduce ATP-evoked nociceptor activation. This receptor is important for peripheral pain responses, and also participates in pathways controlling urinary bladder volume reflexes.
The report 'P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2019' outlays comprehensive information on the P2X Purinoceptor 3 (P2RX3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 4 and 3 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.
Report covers products from therapy areas Central Nervous System, Respiratory, Women's Health, Dermatology and Ophthalmology which include indications Chronic Cough, Pain, Neuropathic Pain (Neuralgia), Visceral Pain, Endometriosis, Inflammatory Pain, Alzheimer's Disease, Cough, Insomnia, Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), Obstructive Sleep Apnea, Ocular Hypertension, Open-Angle Glaucoma, Osteoarthritis Pain and Pruritus.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 3 (P2RX3)
- The report reviews P2X Purinoceptor 3 (P2RX3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics and enlists all their major and minor projects
- The report assesses P2X Purinoceptor 3 (P2RX3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to P2X Purinoceptor 3 (P2RX3) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 3 (P2RX3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 3 (P2RX3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
P2X Purinoceptor 3 (P2RX3) - Overview
P2X Purinoceptor 3 (P2RX3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
P2X Purinoceptor 3 (P2RX3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
P2X Purinoceptor 3 (P2RX3) - Companies Involved in Therapeutics Development
Bayer AG
Beijing Tide Pharmaceutical Co Ltd
Integral Molecular Inc
Merck & Co Inc
Neurim Pharmaceuticals Ltd
Ossianix Inc
Pfizer Inc
Shionogi & Co Ltd
P2X Purinoceptor 3 (P2RX3) - Drug Profiles
BAY-1817080 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1902607 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gefapixant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Antagonize P2X3 Receptor for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize P2X2 and P2X3 for Visceral Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-5937 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OSX-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OSX-300 Backups - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
piromelatine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-600918 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize P2X3 for Inflammatory Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize P2X3 Receptor for Chronic Pain and Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize P2X3 for Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TDI-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P2X Purinoceptor 3 (P2RX3) - Dormant Products
P2X Purinoceptor 3 (P2RX3) - Discontinued Products
P2X Purinoceptor 3 (P2RX3) - Product Development Milestones
Featured News & Press Releases
Aug 26, 2019: BELLUS Health strengthens leadership team with appointment of Dr. Catherine Bonuccelli, MD as Chief Medical Officer
Jul 31, 2019: Bellus Health starts recruitment in Phase II chronic cough trial
Jul 25, 2019: Evotec SE: P2X3 antagonist demonstrates efficacy against refractory chronic cough in Phase II (POC)
Jul 25, 2019: Positive Phase II data for P2X3 antagonist in patients with refractory chronic cough
Jul 15, 2019: BELLUS Health convenes KOL meeting to discuss the state of chronic cough treatment
May 21, 2019: BELLUS Health presents Phase 1 data for BLU-5937, its lead product candidate for the treatment of refractory chronic cough, at the American Thoracic Society International Conference
May 15, 2019: BELLUS Health to present at three upcoming healthcare investor conferences
May 08, 2019: BELLUS Health provides update on its chronic cough drug candidate BLU-5937
Apr 04, 2019: BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences
Apr 03, 2019: BELLUS Health announces clearance of U.S. IND for BLU-5937 phase 2 study in chronic cough patients
Dec 12, 2018: Altasciences Contributes to Positive Top-Line Phase 1 Results for Chronic Cough Drug Candidate
Nov 14, 2018: BELLUS Health updates BLU-5937 top-line phase 1 results timeline to November 2018
Oct 31, 2018: Bellus health announces issuance of new U.S. patent claiming P2X3 selectivity as a means of minimizing taste effects for its lead chronic cough drug candidate BLU-5937
Sep 25, 2018: BELLUS Health announces appointment of clinical advisory board
Jul 19, 2018: BELLUS Health Announces Patent Protection Secured in All Major Pharmaceutical Markets for Lead Drug Candidate BLU-5937
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
P2X Purinoceptor 3 (P2RX3) - Overview
P2X Purinoceptor 3 (P2RX3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
P2X Purinoceptor 3 (P2RX3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
P2X Purinoceptor 3 (P2RX3) - Companies Involved in Therapeutics Development
Bayer AG
Beijing Tide Pharmaceutical Co Ltd
Integral Molecular Inc
Merck & Co Inc
Neurim Pharmaceuticals Ltd
Ossianix Inc
Pfizer Inc
Shionogi & Co Ltd
P2X Purinoceptor 3 (P2RX3) - Drug Profiles
BAY-1817080 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1902607 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gefapixant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Antagonize P2X3 Receptor for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize P2X2 and P2X3 for Visceral Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-5937 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OSX-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OSX-300 Backups - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
piromelatine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-600918 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize P2X3 for Inflammatory Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize P2X3 Receptor for Chronic Pain and Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize P2X3 for Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TDI-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P2X Purinoceptor 3 (P2RX3) - Dormant Products
P2X Purinoceptor 3 (P2RX3) - Discontinued Products
P2X Purinoceptor 3 (P2RX3) - Product Development Milestones
Featured News & Press Releases
Aug 26, 2019: BELLUS Health strengthens leadership team with appointment of Dr. Catherine Bonuccelli, MD as Chief Medical Officer
Jul 31, 2019: Bellus Health starts recruitment in Phase II chronic cough trial
Jul 25, 2019: Evotec SE: P2X3 antagonist demonstrates efficacy against refractory chronic cough in Phase II (POC)
Jul 25, 2019: Positive Phase II data for P2X3 antagonist in patients with refractory chronic cough
Jul 15, 2019: BELLUS Health convenes KOL meeting to discuss the state of chronic cough treatment
May 21, 2019: BELLUS Health presents Phase 1 data for BLU-5937, its lead product candidate for the treatment of refractory chronic cough, at the American Thoracic Society International Conference
May 15, 2019: BELLUS Health to present at three upcoming healthcare investor conferences
May 08, 2019: BELLUS Health provides update on its chronic cough drug candidate BLU-5937
Apr 04, 2019: BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences
Apr 03, 2019: BELLUS Health announces clearance of U.S. IND for BLU-5937 phase 2 study in chronic cough patients
Dec 12, 2018: Altasciences Contributes to Positive Top-Line Phase 1 Results for Chronic Cough Drug Candidate
Nov 14, 2018: BELLUS Health updates BLU-5937 top-line phase 1 results timeline to November 2018
Oct 31, 2018: Bellus health announces issuance of new U.S. patent claiming P2X3 selectivity as a means of minimizing taste effects for its lead chronic cough drug candidate BLU-5937
Sep 25, 2018: BELLUS Health announces appointment of clinical advisory board
Jul 19, 2018: BELLUS Health Announces Patent Protection Secured in All Major Pharmaceutical Markets for Lead Drug Candidate BLU-5937
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Bayer AG, H2 2019
Pipeline by Beijing Tide Pharmaceutical Co Ltd, H2 2019
Pipeline by Integral Molecular Inc, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Neurim Pharmaceuticals Ltd, H2 2019
Pipeline by Ossianix Inc, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Shionogi & Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Bayer AG, H2 2019
Pipeline by Beijing Tide Pharmaceutical Co Ltd, H2 2019
Pipeline by Integral Molecular Inc, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Neurim Pharmaceuticals Ltd, H2 2019
Pipeline by Ossianix Inc, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Shionogi & Co Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Bayer AG
Beijing Tide Pharmaceutical Co Ltd
Integral Molecular Inc
Merck & Co Inc
Neurim Pharmaceuticals Ltd
Ossianix Inc
Pfizer Inc
Shionogi & Co Ltd
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Bayer AG
Beijing Tide Pharmaceutical Co Ltd
Integral Molecular Inc
Merck & Co Inc
Neurim Pharmaceuticals Ltd
Ossianix Inc
Pfizer Inc
Shionogi & Co Ltd
